1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxyisoquinoline | 76351-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxyisoquinoline
• 英文别名: (+)-1,2,3,4-Tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenyl-methyl)-6,7-methylenedioxyisoquinoline；[2,3-dimethoxy-6-(5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-ylmethyl)phenyl]methanol
• CAS: 76351-81-0
• 化学式: C₂₀H₂₃NO₅
• 分子量: 357.406
• InChiKey: GEYIGOSFVDQUCC-UHFFFAOYSA-N

物化性质

• 沸点：
  520.9±50.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxyisoquinoline 以 水 、 溶剂黄146 为溶剂， 反应 3.5h， 以90%的产率得到5,8,13,13a-tetrahydro-12-hydroxymethyl-10,11-dimethoxy-2,3-methylenedioxy-6H-dibenzoquinolizine
  参考文献：
  名称：

  Hanaoka, Miyoji; Nagami, Kazuyoshi; Inoue, Mitsuru, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 8, p. 2685 - 2690

  摘要：

  DOI：
• 作为产物：
  描述：

  四氢小檗碱 在 aluminum oxide 、 氢氧化钾 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 103.0h， 生成 1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxyisoquinoline
  参考文献：
  名称：

  Hanaoka, Miyoji; Nagami, Kazuyoshi; Inoue, Mitsuru, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 8, p. 2685 - 2690

  摘要：

  DOI：

文献信息

• [EN] THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD<br/>[FR] COMPOSES THERAPEUTIQUES AVEC ECHAFAUDAGE PYRIDINE N OXYDE
  申请人：ASTRAZENECA AB

  公开号：WO2005115987A1

  公开（公告）日：2005-12-08

  Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  化学式为I的化合物或其药学上可接受的盐：其中R1、R2、R3、R4、m和n如规范中所定义，以及制备该化合物的盐和药物组成物。它们在治疗中有用，特别是在疼痛管理方面。
• Hanaoka, Miyoji; Inoue, Mitsuru; Yasuda, Shingo, Heterocycles, 1980, vol. 14, # 11, p. 1791 - 1792
  作者：Hanaoka, Miyoji、Inoue, Mitsuru、Yasuda, Shingo、Imanishi, Takeshi

  DOI：——

  日期：——
• THERAPEUTIC COMPOUNDS: PYRIDINE N OXIDE SCAFFOLD
  申请人：AstraZeneca AB

  公开号：EP1756061A1

  公开（公告）日：2007-02-28
• A PURIFIED ARABINOGALACTAN-PROTEIN (AGP) COMPOSITION
  申请人：Lupin Limited

  公开号：EP1789439A1

  公开（公告）日：2007-05-30
• Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders
  申请人：Arora Kumar Sudershan

  公开号：US20060045930A1

  公开（公告）日：2006-03-02

  A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).